These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

826 related items for PubMed ID: 29411879

  • 1. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
    Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ.
    J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
    [Abstract] [Full Text] [Related]

  • 2. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
    Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y.
    Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
    [Abstract] [Full Text] [Related]

  • 3. Hyperforin in St. John's wort drug interactions.
    Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V.
    Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
    [Abstract] [Full Text] [Related]

  • 4. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study.
    Wright CW, Gott M, Grayson B, Hanna M, Smith AG, Sunter A, Neill JC.
    J Psychopharmacol; 2003 Dec; 17(4):403-8. PubMed ID: 14870952
    [Abstract] [Full Text] [Related]

  • 5. Optimization of Light Intensity, Temperature, and Nutrients to Enhance the Bioactive Content of Hyperforin and Rutin in St. John's Wort.
    Kuo CH, Chou YC, Liao KC, Shieh CJ, Deng TS.
    Molecules; 2020 Sep 16; 25(18):. PubMed ID: 32948004
    [Abstract] [Full Text] [Related]

  • 6. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin.
    Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B.
    Clin Pharmacol Ther; 2004 Jun 16; 75(6):546-57. PubMed ID: 15179409
    [Abstract] [Full Text] [Related]

  • 7. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).
    Markowitz JS, DeVane CL.
    Psychopharmacol Bull; 2001 Jun 16; 35(1):53-64. PubMed ID: 12397870
    [Abstract] [Full Text] [Related]

  • 8. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
    Wang EJ, Barecki-Roach M, Johnson WW.
    J Pharm Pharmacol; 2004 Jan 16; 56(1):123-8. PubMed ID: 14980009
    [Abstract] [Full Text] [Related]

  • 9. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
    Soleymani S, Bahramsoltani R, Rahimi R, Abdollahi M.
    Expert Opin Drug Metab Toxicol; 2017 Oct 16; 13(10):1047-1062. PubMed ID: 28885074
    [Abstract] [Full Text] [Related]

  • 10. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.
    Schempp CM, Winghofer B, Lüdtke R, Simon-Haarhaus B, Schöpf E, Simon JC.
    Br J Dermatol; 2000 May 16; 142(5):979-84. PubMed ID: 10809859
    [Abstract] [Full Text] [Related]

  • 11. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
    Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M.
    J Am Pharm Assoc (Wash); 2001 May 16; 41(4):560-6. PubMed ID: 11486982
    [Abstract] [Full Text] [Related]

  • 12. Drug interactions with St John's wort : mechanisms and clinical implications.
    Mannel M.
    Drug Saf; 2004 May 16; 27(11):773-97. PubMed ID: 15350151
    [Abstract] [Full Text] [Related]

  • 13. St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants.
    Klier CM, Schmid-Siegel B, Schäfer MR, Lenz G, Saria A, Lee A, Zernig G.
    J Clin Psychiatry; 2006 Feb 16; 67(2):305-9. PubMed ID: 16566628
    [Abstract] [Full Text] [Related]

  • 14. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
    Ng QX, Venkatanarayanan N, Ho CY.
    J Affect Disord; 2017 Mar 01; 210():211-221. PubMed ID: 28064110
    [Abstract] [Full Text] [Related]

  • 15. Current St John's wort research from mode of action to clinical efficacy.
    Müller WE.
    Pharmacol Res; 2003 Feb 01; 47(2):101-9. PubMed ID: 12543057
    [Abstract] [Full Text] [Related]

  • 16. Modulation of P-glycoprotein function by St John's wort extract and its major constituents.
    Weber CC, Kressmann S, Fricker G, Müller WE.
    Pharmacopsychiatry; 2004 Nov 01; 37(6):292-8. PubMed ID: 15551196
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic interactions of drugs with St John's wort.
    Zhou S, Chan E, Pan SQ, Huang M, Lee EJ.
    J Psychopharmacol; 2004 Jun 01; 18(2):262-76. PubMed ID: 15260917
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.
    Schulte-Löbbert S, Holoubek G, Müller WE, Schubert-Zsilavecz M, Wurglics M.
    J Pharm Pharmacol; 2004 Jun 01; 56(6):813-8. PubMed ID: 15231048
    [Abstract] [Full Text] [Related]

  • 19. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
    Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B.
    Eur J Clin Pharmacol; 2006 Jan 01; 62(1):29-36. PubMed ID: 16341856
    [Abstract] [Full Text] [Related]

  • 20. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
    Schulz HU, Schürer M, Bässler D, Weiser D.
    Arzneimittelforschung; 2005 Jan 01; 55(10):561-8. PubMed ID: 16294501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.